vaccination

Researchers have warned that the United States has not yet reached the necessary thresholds for achieving population immunity against severe acute respiratory coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19). The team – from RTI International in Research Triangle Park, North Carolina, and Pfizer Inc. in Collegeville, Pennsylvania – says that
0 Comments
NEW YORK and MAINZ, GERMANY, December 12, 2020 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted today to recommend the use of the Pfizer-BioNTech COVID-19 vaccine in people 16 years of age and older under the Emergency Use Authorization
0 Comments
As the coronavirus disease (COVID-19) threatens the globe infecting over 43.8 million people, the development of a vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is of paramount importance. Apart from the dissemination of the vaccine, its acceptance among the public is also crucial. Obtaining a high uptake of the vaccine will be
0 Comments